Idexx Laboratories (IDXX) EBT (2009 - 2026)

Idexx Laboratories' EBT history runs 18 years deep, the most recent figure standing at $355.4 million for Q1 2026.

• In Q1 2026, EBT rose 14.63% year-over-year to $355.4 million; the TTM figure through Mar 2026 stood at $1.4 billion (up 21.8% YoY), while the FY2025 annual figure was $1.3 billion, up 19.31% from the prior year.
• EBT for Q1 2026 stood at $355.4 million, up from $307.0 million in the prior quarter.
• The five-year high for EBT was $362.4 million in Q2 2025, with the low at $171.1 million in Q2 2022.
• The 5-year median for EBT is $267.9 million (2023), against an average of $277.1 million.
• The sharpest annual moves came in 2022 and 2023: EBT sank 32.04% in 2022, then surged 67.13% in 2023.
• Idexx Laboratories' EBT stood at $213.2 million in 2022, then increased by 12.41% to $239.7 million in 2023, then gained by 6.98% to $256.4 million in 2024, then grew by 19.73% to $307.0 million in 2025, then climbed by 15.79% to $355.4 million in 2026.
• Business Quant data shows IDXX's EBT at $355.4 million in Q1 2026, $307.0 million in Q4 2025, and $344.8 million in Q3 2025.